Compare CIG & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIG | GKOS |
|---|---|---|
| Founded | 1952 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | N/A | 2015 |
| Metric | CIG | GKOS |
|---|---|---|
| Price | $2.05 | $108.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $123.62 |
| AVG Volume (30 Days) | ★ 2.9M | 860.2K |
| Earning Date | 03-19-2026 | 10-29-2025 |
| Dividend Yield | ★ 10.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $7,960,960,695.00 | $469,820,000.00 |
| Revenue This Year | N/A | $31.15 |
| Revenue Next Year | N/A | $24.15 |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | 9.92 | ★ 30.38 |
| 52 Week Low | $1.59 | $73.16 |
| 52 Week High | $2.30 | $163.71 |
| Indicator | CIG | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 70.89 |
| Support Level | $1.98 | $105.88 |
| Resistance Level | $2.16 | $110.87 |
| Average True Range (ATR) | 0.04 | 3.39 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 37.14 | 80.77 |
Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.